$IMNM
Immunome Inc.

2020 Q4 Form 10-Q Financial Statement

#000155837020013895 Filed on November 16, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.240M $1.170M $1.525M
YoY Change 46.89% 138.78%
% of Gross Profit
Research & Development $1.840M $1.644M $8.823M
YoY Change -79.15% -26.41%
% of Gross Profit
Depreciation & Amortization $260.0K $180.0K $320.0K
YoY Change -18.75% 20.0%
% of Gross Profit
Operating Expenses $4.070M $2.818M $10.35M
YoY Change -60.67% 3.6%
Operating Profit -$2.818M
YoY Change 3.6%
Interest Expense $0.00 -$5.560M -$96.00K
YoY Change -100.0% 27700.0%
% of Operating Profit
Other Income/Expense, Net $5.559M
YoY Change 32600.0%
Pretax Income -$4.070M -$8.380M -$10.44M
YoY Change -61.03% 205.84%
Income Tax
% Of Pretax Income
Net Earnings -$4.070M -$8.377M -$10.44M
YoY Change -61.03% 206.07%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$381.8K -$795.1K -$1.125M
COMMON SHARES
Basic Shares Outstanding 10.54M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.77M $6.740M
YoY Change
Cash & Equivalents $39.77M $6.744M $2.543M
Short-Term Investments
Other Short-Term Assets $3.130M $740.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $42.89M $7.483M $3.122M
YoY Change 1273.93%
LONG-TERM ASSETS
Property, Plant & Equipment $1.531M $1.741M $1.700M
YoY Change -9.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $2.659M $138.0K
YoY Change -27.54%
Total Long-Term Assets $1.631M $4.500M $1.938M
YoY Change -15.84%
TOTAL ASSETS
Total Short-Term Assets $42.89M $7.483M $3.122M
Total Long-Term Assets $1.631M $4.500M $1.938M
Total Assets $44.53M $11.98M $5.060M
YoY Change 779.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.187M $2.627M $548.0K
YoY Change 116.61%
Accrued Expenses $1.372M $2.330M $666.0K
YoY Change 106.01% 249.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $366.0K $305.0K
YoY Change
Total Short-Term Liabilities $3.038M $5.406M $1.665M
YoY Change 82.46%
LONG-TERM LIABILITIES
Long-Term Debt $134.0K $195.0K
YoY Change
Other Long-Term Liabilities $10.00K $7.080M
YoY Change
Total Long-Term Liabilities $134.0K $195.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.038M $5.406M $1.665M
Total Long-Term Liabilities $134.0K $195.0K
Total Liabilities $3.180M $12.70M $1.796M
YoY Change 77.06%
SHAREHOLDERS EQUITY
Retained Earnings -$54.40M -$50.30M -$36.60M
YoY Change 48.63%
Common Stock $1.000K $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $41.35M -$49.09M -$35.63M
YoY Change
Total Liabilities & Shareholders Equity $44.53M $11.98M $5.060M
YoY Change 779.94%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$4.070M -$8.377M -$10.44M
YoY Change -61.03% 206.07%
Depreciation, Depletion And Amortization $260.0K $180.0K $320.0K
YoY Change -18.75% 20.0%
Cash From Operating Activities -$6.060M -$2.530M -$4.940M
YoY Change 22.67% 7.2%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$120.0K -$190.0K
YoY Change -73.68% -192.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$50.00K -$120.0K -$190.0K
YoY Change -73.68% -7.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $41.70M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.13M -400.0K 4.420M
YoY Change 785.29%
NET CHANGE
Cash From Operating Activities -6.060M -2.530M -4.940M
Cash From Investing Activities -50.00K -120.0K -190.0K
Cash From Financing Activities 39.13M -400.0K 4.420M
Net Change In Cash 33.02M -3.050M -710.0K
YoY Change -4750.7% 22.49%
FREE CASH FLOW
Cash From Operating Activities -$6.060M -$2.530M -$4.940M
Capital Expenditures -$50.00K -$120.0K -$190.0K
Free Cash Flow -$6.010M -$2.410M -$4.750M
YoY Change 26.53% -3.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Central Index Key
EntityCentralIndexKey
0001472012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1124616
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1099270
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39580
dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
321-3700
dei Security12b Title
Security12bTitle
Common Stock, 0.0001 par value
dei Trading Symbol
TradingSymbol
IMNM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10541629
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6744000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2543000
CY2020Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
739000
CY2019Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
579000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
7483000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
3122000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1741000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1700000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2659000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
138000
CY2020Q3 us-gaap Assets
Assets
11983000
CY2019Q4 us-gaap Assets
Assets
5060000
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
239000
CY2020Q3 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
144000
CY2019Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
212000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
305000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2627000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
548000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2330000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
666000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5406000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1665000
CY2020Q3 imnm Equipment Loan Payable Net Of Current Portion
EquipmentLoanPayableNetOfCurrentPortion
16000
CY2019Q4 imnm Equipment Loan Payable Net Of Current Portion
EquipmentLoanPayableNetOfCurrentPortion
113000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
195000
CY2020Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7071000
CY2020Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
11000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
18000
CY2020Q3 us-gaap Liabilities
Liabilities
12699000
CY2019Q4 us-gaap Liabilities
Liabilities
1796000
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
48369000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
38894000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
65000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1124616
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1099270
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1236000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
927000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50321000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36557000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-49085000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11983000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5060000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1644000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2234000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5651000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6391000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1174000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
486000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2537000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1069000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2818000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
2720000
us-gaap Operating Expenses
OperatingExpenses
8188000
us-gaap Operating Expenses
OperatingExpenses
7460000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2818000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2720000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8188000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7460000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-40829000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
117000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-49085000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-29980000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2737000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8377000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-49085000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
302000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-17000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-27000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-62000
CY2020Q3 us-gaap Other Expenses
OtherExpenses
5559000
CY2019Q3 us-gaap Other Expenses
OtherExpenses
17000
us-gaap Other Expenses
OtherExpenses
5576000
us-gaap Other Expenses
OtherExpenses
62000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-8377000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2737000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
us-gaap Net Income Loss
NetIncomeLoss
-7522000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.52
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-12.44
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.88
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1114427
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1093028
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1106039
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1092630
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-32716000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-25205000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11000
us-gaap Net Income Loss
NetIncomeLoss
-7522000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-32716000
us-gaap Net Income Loss
NetIncomeLoss
-13764000
us-gaap Net Income Loss
NetIncomeLoss
-7522000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
499000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
454000
us-gaap Share Based Compensation
ShareBasedCompensation
302000
us-gaap Share Based Compensation
ShareBasedCompensation
11000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5549000
imnm Deferred Rent
DeferredRent
-1000
imnm Deferred Rent
DeferredRent
3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
151000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
249000
us-gaap Interest Paid Net
InterestPaidNet
72000
imnm Liability Classified Warrants Issued In Connection With Convertible Preferred Stock Fair Value
LiabilityClassifiedWarrantsIssuedInConnectionWithConvertiblePreferredStockFairValue
1522000
imnm Non Cash Transactions Convertible Preferred Stock And Warrants Issuance Costs In Accounts Payable
NonCashTransactionsConvertiblePreferredStockAndWarrantsIssuanceCostsInAccountsPayable
22000
imnm Stock Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities Current
StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilitiesCurrent
2221000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41700000
imnm Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3100000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Net Income Loss
NetIncomeLoss
-13800000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
999000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
334000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
495000
imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-52000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6072000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7021000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
540000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
166000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-540000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-166000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
6800000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
500000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11046000
imnm Payments Of Stock Issuance Costs Relating To Temporary Equity
PaymentsOfStockIssuanceCostsRelatingToTemporaryEquity
309000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
27000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
165000
imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
183000
imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
239000
imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
272000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10813000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6345000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4201000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-842000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1702000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6844000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
860000
us-gaap Interest Paid Net
InterestPaidNet
27000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50300000
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
6
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair value of the Company’s common stock in connection with share-based compensation arrangements and the fair value of the Company’s liability-classified warrants. Actual results could differ from these estimates.</p>
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5500000
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5500000
CY2020Q3 us-gaap Share Price
SharePrice
12.00
imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2019Q3 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2020Q3 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8021647
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3701705
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020Q3 imnm Initial Public Offering Costs
InitialPublicOfferingCosts
1165000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
831000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
426000
CY2020Q3 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
334000
CY2019Q3 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
240000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2330000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
666000
us-gaap Debt Instrument Frequency Of Periodic Payment
DebtInstrumentFrequencyOfPeriodicPayment
monthly
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
55000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
333000
CY2020Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
112000
CY2020Q3 us-gaap Long Term Debt
LongTermDebt
500000
CY2020Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
305000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
195000
CY2020Q3 us-gaap Payments For Rent
PaymentsForRent
100000
CY2019Q3 us-gaap Payments For Rent
PaymentsForRent
100000
us-gaap Payments For Rent
PaymentsForRent
200000
us-gaap Payments For Rent
PaymentsForRent
200000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
34000
CY2020Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
302000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M25D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.822
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.743
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.025
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
CY2020Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
1.95
CY2019Q3 imnm Fair Value Of Common Stock
FairValueOfCommonStock
0.38
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.69
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
800000

Files In Submission

Name View Source Status
0001558370-20-013895-index-headers.html Edgar Link pending
0001558370-20-013895-index.html Edgar Link pending
0001558370-20-013895.txt Edgar Link pending
0001558370-20-013895-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20200930.xsd Edgar Link pending
tmb-20200930x10q.htm Edgar Link pending
tmb-20200930x10q_htm.xml Edgar Link completed
tmb-20200930xex10d17.htm Edgar Link pending
tmb-20200930xex31d1.htm Edgar Link pending
tmb-20200930xex31d2.htm Edgar Link pending
tmb-20200930xex32d1.htm Edgar Link pending
tmb-20200930xex32d2.htm Edgar Link pending
tmb-20200930_cal.xml Edgar Link unprocessable
tmb-20200930_def.xml Edgar Link unprocessable
tmb-20200930_lab.xml Edgar Link unprocessable
tmb-20200930_pre.xml Edgar Link unprocessable